Literature DB >> 22940378

The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Terri B Hyde1, Holly Dentz, Susan A Wang, Helen E Burchett, Sandra Mounier-Jack, Carsten F Mantel.   

Abstract

We conducted a systematic review of the published literature to examine the impact of new vaccine introduction on countries' immunization and broader health systems. Six publication databases were searched using 104 vaccine and health system-related search terms. The search yielded 15,795 unique articles dating from December 31, 1911 to September 29, 2010. Based on review of the title and abstract, 654 (4%) of these articles were found to be potentially relevant and were referred for full review. After full review, 130 articles were found to be relevant and included in the analysis. These articles represented vaccines introduced to protect against 10 different diseases (hepatitis A, hepatitis B, Haemophilus influenzae type b disease, human papilloma virus infection, influenza, Japanese encephalitis, meningococcal meningitis, Streptococcus pneumoniae disease, rotavirus diarrhea and typhoid), in various formulations and combinations. Most reviewed articles (97 [75%]) reported experiences in high-income countries. New vaccine introduction was most efficient when the vaccine was introduced into an existing delivery platform and when introduced in combination with a vaccine already in the routine childhood immunization schedule (i.e., as a combination vaccine). New vaccine introduction did not impact coverage of vaccines already included in the routine childhood immunization schedule. The need for increased cold chain capacity was frequently reported. New vaccines facilitated the introduction and widespread use of auto-disable syringes into the immunization and the broader health systems. The importance of training and education for health care workers and social mobilization was frequently noted. There was evidence in high-income countries that new vaccine introduction was associated with reduced health-care costs. Future evaluations of new vaccine introductions should include the systematic and objective assessment of the impacts on a country's immunization system and broader health system, especially in lower-income countries. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22940378      PMCID: PMC4655431          DOI: 10.1016/j.vaccine.2012.08.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  124 in total

Review 1.  Hib conjugate vaccines: lessons learned.

Authors:  D Scheifele
Journal:  Int J Clin Pract Suppl       Date:  2001-02

2.  [Impact of vaccination against Haemophilus influenzae type b in Cuba].

Authors:  F O Dickinson; A E Pérez; M A Galindo; I Quintana
Journal:  Rev Panam Salud Publica       Date:  2001-09

3.  Impact of non-routine vaccination on the incidence of invasive Haemophilus influenzae type b (Hib) disease: experience in the autonomous region of Valencia, Spain.

Authors:  J Díez-Domingo; I Pereiró; A Morant; C Gimeno; M San-Martín; A González
Journal:  J Infect       Date:  2001-05       Impact factor: 6.072

Review 4.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

5.  Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.

Authors:  Philippe De Wals; Lonny Erickson
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

6.  GAVI, the first steps: lessons for the Global Fund.

Authors:  Ruairí Brugha; Mary Starling; Gill Walt
Journal:  Lancet       Date:  2002-02-02       Impact factor: 79.321

7.  Introduction of a conjugate meningococcal type C vaccine programme in the UK.

Authors:  D Salisbury
Journal:  J Paediatr Child Health       Date:  2001-10       Impact factor: 1.954

8.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Authors:  E Miller; D Salisbury; M Ramsay
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

9.  Effectiveness of the meningococcal vaccination programme for British Armed Forces recruits.

Authors:  B P Bergman; J C Hayton; A D Green
Journal:  Commun Dis Public Health       Date:  2000-12

10.  Effectiveness of a mass hepatitis A vaccination program in preadolescents.

Authors:  Angela Domínguez; Lluís Salleras; Glòria Carmona; Juan Batalla
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

View more
  19 in total

1.  Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999-2014).

Authors:  Gian Gandhi
Journal:  BMC Public Health       Date:  2015-11-30       Impact factor: 3.295

Review 2.  New vaccine introductions: assessing the impact and the opportunities for immunization and health systems strengthening.

Authors:  Susan A Wang; Terri B Hyde; Sandra Mounier-Jack; Logan Brenzel; Michael Favin; W Scott Gordon; Jessica C Shearer; Carsten F Mantel; Narendra Arora; David Durrheim
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

3.  New pneumococcal conjugate vaccine introductions in four sub-Saharan African countries: a cross-country analysis of health systems' impacts.

Authors:  Sergio Torres-Rueda; Helen Ed Burchett; Ulla K Griffiths; Pierre Ongolo-Zogo; Jean-Marie Edengue; Yayehyirad Kitaw; Mitike Molla; Lawrence Gelmon; Washington Onyango-Ouma; Mamadou Konate; Sandra Mounier-Jack
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

4.  Four new vaccines for routine immunization in India: what about hemophilus influenza B and pneumococcal vaccine?

Authors:  Sourabh Paul; Jyotiranjan Sahoo
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar

5.  Meningococcal vaccine introduction in Mali through mass campaigns and its impact on the health system.

Authors:  Sandra Mounier-Jack; Helen Elizabeth Denise Burchett; Ulla Kou Griffiths; Mamadou Konate; Kassibo Sira Diarra
Journal:  Glob Health Sci Pract       Date:  2014-01-15

6.  Can a Compact Pre-Filled Auto-Disable Injection System (cPAD) Save Costs for DTP-HepB-Hib Vaccine as Compared with Single-Dose (SDV) and Multi-Dose Vials (MDV)? Evidence from Cambodia, Ghana, and Peru.

Authors:  Cyril Nogier; Patrick Hanlon; Karin Wiedenmayer; Nicolas Maire
Journal:  Drugs Real World Outcomes       Date:  2015-03

7.  The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi.

Authors:  B Adam Williams; Teklay Kidane; Geoffrey Chirwa; Neghist Tesfaye; Marta R Prescott; Soleine T Scotney; Moussa Valle; Sintayehu Abebe; Adija Tambuli; Bridget Malewezi; Tahir Mohammed; Emily Kobayashi; Emily Wootton; Renee Wong; Rahima Dosani; Hamsa Subramaniam; Jessica Joseph; Elif Yavuz; Aliza Apple; Yann Le Tallec; Alice Kang'ethe
Journal:  Health Policy Plan       Date:  2016-02-07       Impact factor: 3.344

8.  How a New Health Intervention Affects the Health Systems? Learnings from Pentavalent Vaccine Introduction in India.

Authors:  Chandrakant Lahariya; Renu Paruthi; Madhulekha Bhattacharya
Journal:  Indian J Pediatr       Date:  2015-08-13       Impact factor: 1.967

9.  Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.

Authors:  Eduardo Suarez-Castaneda; Eleanor Burnett; Miguel Elas; Rafael Baltrons; Lorenzo Pezzoli; Brendan Flannery; David Kleinbaum; Lucia Helena de Oliveira; M Carolina Danovaro-Holliday
Journal:  Vaccine       Date:  2015-08-08       Impact factor: 3.641

10.  Measuring the health systems impact of disease control programmes: a critical reflection on the WHO building blocks framework.

Authors:  Sandra Mounier-Jack; Ulla K Griffiths; Svea Closser; Helen Burchett; Bruno Marchal
Journal:  BMC Public Health       Date:  2014-03-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.